Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

OBJECTIVE: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). METHODS: In this phase III randomized, double‐blind, placebo‐controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Poddubnyy, Denis, Pacheco‐Tena, Cesar, Salvarani, Carlo, Lespessailles, Eric, Rahman, Proton, Järvinen, Pentti, Sanchez‐Burson, Juan, Gaffney, Karl, Lee, Eun Bong, Krishnan, Eswar, Santisteban, Silvia, Li, Xiaoqi, Zhao, Fangyi, Carlier, Hilde, Reveille, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593790/
https://www.ncbi.nlm.nih.gov/pubmed/30343531
http://dx.doi.org/10.1002/art.40753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593790/
https://www.ncbi.nlm.nih.gov/pubmed/30343531
http://dx.doi.org/10.1002/art.40753

Ejemplares similares